Ultrasonic Method for Testing Anti Sickling Agents

描述(由申请人提供)：第一阶段工作的结果，在 对7例血瘀证患者的血样进行了检测， 确定了使用相敏声学检测的可行性 HbSS聚合的定量监测技术。的影响 引入抗镰刀剂也在结果中得到了明确的解决。在……里面 此外，对5个正常血液样本进行了声学测量 通过演示可重复性展示了技术的敏感性 对正常血液脱氧的微小声学响应的分辨。 随着基本反应问题的解决，第二阶段的主要目标是 将努力开发一种可供第三人使用的实验室原型 党支持抗病药物研究努力，通用镰刀细胞 研究，并有可能被用作潜在的诊断工具 临床环境。为了实现这一目标，应采取以下具体措施 将在第二阶段：1下实现目标。改进的实验原型将 被设计好。2.稳定和可重复的测试底物(细胞悬浮液)将 被开发出来。3.该装置将在以下方面进行广泛的表征 校准、灵敏度和样品变异性。4.社会福利制度的影响 大量的抗病毒剂将被测量。 建议的商业应用： 不可用

DESCRIPTION (provided by applicant): The results of the Phase I effort, during the course of which the blood samples of 7 HbSS patients were examined, established the feasibility of using phase-sensitive acoustic detection techniques to quantitatively monitor the polymerization of HbSS. The effects of introducing anti-sickling agents were also clearly resolved in the results. In addition, the acoustic measurements performed on 5 normal blood samples revealed the techniques sensitivity by demonstrating the reproducible resolution of the minute acoustic response to de-oxygenation of normal blood. With the basic response question settled, the primary aim of the Phase II effort will be to develop a laboratory prototype that can be used by a third party to support anti-sickling drug research efforts, general sickle cell research, as well as be potentially used as a potential diagnostic tool in clinical settings. In order to accomplish this goal, the following specific aims will be pursued under Phase II: 1. An improved experimental prototype will be designed. 2. A stable and repeatable test substrate (cell suspension) will be developed. 3. The device will be characterized extensively with regard to calibration, sensitivity, and sample variability. 4. The effects of an extensive number of anti-sickling agents will be measured. PROPOSED COMMERCIAL APPLICATION: Not Available